The long-term goal of AIDSFree is to improve the quality and effectiveness of high-impact, evidence-informed HIV and AIDS interventions. This semiannual performance report (SAPR) summarizes AIDSFree's achievements for the period October 1, 2015–March 31, 2016
The Strong Families Programme was developed and piloted in Afghanistan thanks to the generous support of the US-INL. To date, this programme has further been piloted in Central America, Central and West Asia, East and West Africa thanks to the support of Sweden, France and the US
2nd edition.
The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide
CBM strategy overview paper on preventing physical impairment in childhood.
In low- and middle-income middle-income countries, reliable and disaggregated disability data on prevalence, participation and barriers are often unavailable. This study aimed to estimate disability prevalence, determine associated socio-demographic factors and compare access in the community betwee...n people with and without disability in Dehradun district of Uttarakhand, India, using the Rapid Assessment of Disability survey.
more
Western Pac Surveill Response J. 2014 Oct-Dec; 5(4): 34–46.
Published online 2014 Dec 18. doi: [10.5365/WPSAR.2014.5.4.007]
Single TB and HIV Concept Note Albania 2016-2018 27 April 2015
PeerJ PrePrints , http://dx.doi.org/10.7287/peerj.preprints.579v1 2 Nov 2014
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Lancet Psychiatry 2016;3: 415–24
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more